top of page

CO-CULTURE SIMPLIFIED

 CO-CULTURE SIMPLIFIED    

CO-CULTUREAPPLICATIONS

Onexio’s innovative  microplate  technology allows co-culture via micro-scale diffusion channels between pairs of wells. This patented design facilitates improved assay relevance in HTS.  Established uses include integrating drug metabolism and other intercellular interactions in a technically simple format for drug/chemical safety and discovery applications. The microDUO design is easily scaled (i.e., 96, 384, 1536-well plate formats and 48, 192 and 768 co-culture assays per plate respectively) in a ANSI/SLAS format that seamlessly integrates into existing automated HTS workflows. Co-culture can easily be initiated and reversed by the addition or removal of media, respectively.  The wells in the microDUO plate can have clear or solid bottoms, allowing a range of assay endpoints on both cell types, (e.g., fluorescence, luminescence, or absorbance) to be measured by a standard plate reader or high-content imager. The microDUO offers a user-friendly assay set-up and while other technologies require extensive handling, equipement and unique expertise, the microDUO only requires the same level of operational knowledge needed for a standard microplate. The microDUO plate has been designed to be a cost-effective alternative to traditional co-culture platforms.

Onexio’s innovative  microplate  technology allows co-culture via micro-scale diffusion channels between pairs of wells. This patented design facilitates improved assay relevance in HTS.  Established uses include integrating drug metabolism and other intercellular interactions in a technically simple format for drug/chemical safety and discovery applications. The microDUO design is easily scaled (i.e., 96, 384, 1536-well plate formats and 48, 192 and 768 co-culture assays per plate respectively) in a ANSI/SLAS format that seamlessly integrates into existing automated HTS workflows. Co-culture can easily be initiated and reversed by the addition or removal of media, respectively.  The wells in the microDUO plate can have clear or solid bottoms, allowing a range of assay endpoints on both cell types, (e.g., fluorescence, luminescence, or absorbance) to be measured by a standard plate reader or high-content imager. The microDUO offers a user-friendly assay set-up and while other technologies require extensive handling, equipement and unique expertise, the microDUO only requires the same level of operational knowledge needed for a standard microplate. The microDUO plate has been designed to be a cost-effective alternative to traditional co-culture platforms.

Onexio Biosystems is developing a high-throughput (96, 384 and 1536 well) microplate platform that supports co-culture and multi-culture to improve human relevance in drug discovery and chemical toxicity testing applications. Known as the microDUO, this versatile platform technology supports the intercellular signaling necessary to improve human relevance, while maintaining full compatibility with standard HTS instrumentation.

THE TECHNOLOGY

CO-FOUNDER/CHIEF EXECUTIVE OFFICER
Tony Jimenez is an entrepreneur with expertise in developing physiologically relevant in vitro models including multi-culture, 3D cell culture, and organotypic models. He holds a PhD in Biomedical Engineering and has more than 12 years of experience in designing microphysiological systems (MPS) for in vitro disease modeling and high-throughput drug screening (HTS). Dr. Jimenez is the lead inventor of the patented microDUO technology. During his tenure at Onexio, he oversaw microDUO's design, fabrication, validation, and assay development. Currently, Dr. Jimenez is focused on enhancing Onexio's product range by devising innovative solutions that increase physiological relevance in vitro, including organoid multi-culture systems.
CO-FOUNDER/CHIEF SCIENTIFIC OFFICER
Brian Johnson’s expertise lies in filling the gap between traditional animal testing models and modern high-throughput screening approaches. Since earning a PhD in Molecular and Environmental Toxicology using mouse models, Brian has gained over 10 years of experience engineering multi-culture and microphysiological models (MPS) to better mimic in vivo biology, in vitro.  At Onexio he earned a top prize in the Transform Tox Testing Challenge for the microDUO concept and its application to incorporate drug metabolism in high-throughput screening.   In his research lab at Michigan State University, his lab creates human derived microphysiological, organotypic and other multi-culture models that reconstruct paracrine and endocrine signaling interactions for hypothesis testing, drug and chemical screening and toxicity testing.